Reliable’s DAA system is built around the FAA’s ACAS X technology—a more sophisticated version of Traffic Alert and Collision Avoidance System II (TCAS II) designed to improve alerting and minimize ...

Rather than relying on passive slides and outdated examples, Amber Book develops courses around real engineering challenges - helping engineers apply lessons immediately on the job: strengthening ...

Police say decision taken due to exceptional circumstances, warn of strict legal action Ras Al Khaimah: Ras Al Khaimah Police have announced a complete ban on operating all types of drones across the ...

ISLAMABAD: The Higher Education Commission (HEC) has urged universities to ensure participation of their advanced-level computing students in the National Skill Competency Test tentatively set for ...

Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people. These ...

A comprehensive, modular Python automation system for HEC-RAS flood analysis workflows. This professional-grade tool demonstrates advanced hydraulic modeling capabilities, Python integration, and ...

Tesla has finally introduced the long-awaited, cheaper versions of its Model Y and Model 3 cars. The new cars, which the company unveiled in an X post on Tuesday, Oct. 7, are the brand’s most ...

Bain Capital agreed to sell its data centers in China to Shenzhen Dongyangguang Industry Co. in a transaction valued at about $4 billion. Shenzhen Dongyangguang, the parent of Shanghai-listed ...

How are businesses building, leveraging, and embedding AI into their day-to-day? This article discusses key considerations when building AI companies or procuring their services. As artificial ...

HEC Compuse Enterprise has gained full control of Poyun after its Hong Kong subsidiary, Honch Electronic, acquired all issued convertible bonds of Amber Investment Partners Limited (AIP), completing ...

Revolution Medicines has secured a potential funding infusion of up to $2 billion from Royalty Pharma in return for a slice of the profits if Revolution’s lead cancer drug makes it to market.